Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
Leukemia
|
December 22, 2017
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
S Bringhen, M D'Agostino, L De Paoli, et al.
Leukemia
|
June 4, 2011
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
F Cavallo, S Bringhen, G Milone, et al.
Journal of Bone Oncology
|
December 11, 2020
Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?
O Annibali, M T Petrucci, D Santini, et al.
Cancer Medicine
|
November 26, 2024
Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study
K Mancuso, R Mina, S Rocchi, et al.
Leukemia
|
December 24, 2016
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
F Gay, S Oliva, M T Petrucci, et al.
Leukemia
|
February 23, 2016
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma
A Larocca, S Bringhen, M T Petrucci, et al.
Oral Diseases
|
January 1, 2017
Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study
Ppl Fung, G Bedogni, A Bedogni, et al.
Leukemia
|
July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
R Hájek, T Masszi, M T Petrucci, et al.
ESMO Open
|
March 12, 2026
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape
F Gay, G Buda, M T Petrucci, et al.
ESMO Open
|
January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients
E A Martino, S Palmieri, M Galli, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
Leukemia
|
December 22, 2017
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
S Bringhen, M D'Agostino, L De Paoli, et al.
Leukemia
|
June 4, 2011
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
F Cavallo, S Bringhen, G Milone, et al.
Journal of Bone Oncology
|
December 11, 2020
Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?
O Annibali, M T Petrucci, D Santini, et al.
Cancer Medicine
|
November 26, 2024
Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study
K Mancuso, R Mina, S Rocchi, et al.
Leukemia
|
December 24, 2016
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
F Gay, S Oliva, M T Petrucci, et al.
Leukemia
|
February 23, 2016
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma
A Larocca, S Bringhen, M T Petrucci, et al.
Oral Diseases
|
January 1, 2017
Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study
Ppl Fung, G Bedogni, A Bedogni, et al.
Leukemia
|
July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
R Hájek, T Masszi, M T Petrucci, et al.
ESMO Open
|
March 12, 2026
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape
F Gay, G Buda, M T Petrucci, et al.
ESMO Open
|
January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients
E A Martino, S Palmieri, M Galli, et al.
Page
of 6